Kindred Biosciences, Inc. (NASDAQ:KIN) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 108,116 shares, a growth of 8.9% from the April 28th total of 99,281 shares. Based on an average daily trading volume, of 70,354 shares, the short-interest ratio is presently 1.5 days.
In other Kindred Biosciences news, major shareholder Park West Asset Management Llc acquired 155,076 shares of the company’s stock in a transaction on Thursday, May 11th. The stock was acquired at an average price of $6.83 per share, for a total transaction of $1,059,169.08. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 19.10% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Kindred Biosciences during the first quarter valued at $102,000. Goldman Sachs Group Inc. raised its stake in Kindred Biosciences by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 4,954 shares during the last quarter. Acadian Asset Management LLC raised its stake in Kindred Biosciences by 51.6% in the first quarter. Acadian Asset Management LLC now owns 29,759 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 10,134 shares during the last quarter. UBS Group AG raised its stake in Kindred Biosciences by 152.7% in the first quarter. UBS Group AG now owns 65,217 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 39,411 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Kindred Biosciences by 6.3% in the first quarter. Geode Capital Management LLC now owns 69,025 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 4,081 shares during the last quarter. 69.53% of the stock is owned by institutional investors.
Kindred Biosciences (KIN) traded down 1.41% during trading on Monday, reaching $7.00. 225,742 shares of the company were exchanged. The company’s market capitalization is $163.17 million. The firm’s 50-day moving average is $6.91 and its 200 day moving average is $6.25. Kindred Biosciences has a one year low of $3.25 and a one year high of $7.55.
Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.04. On average, analysts anticipate that Kindred Biosciences will post ($1.44) EPS for the current fiscal year.
KIN has been the subject of several analyst reports. Zacks Investment Research cut shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a research report on Friday. BMO Capital Markets restated a “hold” rating and issued a $8.00 target price on shares of Kindred Biosciences in a research report on Monday, May 15th. Aegis initiated coverage on shares of Kindred Biosciences in a research report on Friday. They issued a “buy” rating and a $10.50 target price for the company. ValuEngine upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, FBR & Co assumed coverage on shares of Kindred Biosciences in a research report on Wednesday, May 24th. They issued an “outperform” rating and a $10.00 target price for the company. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $8.70.
TRADEMARK VIOLATION NOTICE: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/kindred-biosciences-inc-kin-sees-large-growth-in-short-interest-updated-updated/862827.html.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with our FREE daily email newsletter.